Proteostasis Therapeutics Inc Expected to Earn Q1 2018 Earnings of ($0.49) Per Share (PTI)
Proteostasis Therapeutics Inc (NASDAQ:PTI) – Equities research analysts at Leerink Swann issued their Q1 2018 earnings estimates for Proteostasis Therapeutics in a note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz anticipates that the company will post earnings of ($0.49) per share for the quarter. Leerink Swann also issued estimates for Proteostasis Therapeutics’ Q2 2018 earnings at ($0.48) EPS, Q3 2018 earnings at ($0.46) EPS, Q4 2018 earnings at ($0.47) EPS, FY2018 earnings at ($1.89) EPS, FY2019 earnings at ($1.52) EPS and FY2020 earnings at ($1.57) EPS.
Proteostasis Therapeutics (NASDAQ:PTI) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%.
Shares of Proteostasis Therapeutics (NASDAQ PTI) traded down $0.67 during trading on Thursday, reaching $5.47. The company had a trading volume of 4,317,800 shares, compared to its average volume of 316,455. Proteostasis Therapeutics has a twelve month low of $1.41 and a twelve month high of $16.67.
A number of institutional investors have recently bought and sold shares of the stock. FMR LLC lifted its stake in Proteostasis Therapeutics by 2.3% in the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock valued at $13,782,000 after purchasing an additional 66,111 shares during the last quarter. Jennison Associates LLC lifted its stake in Proteostasis Therapeutics by 6.2% in the second quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock valued at $9,713,000 after purchasing an additional 120,575 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Proteostasis Therapeutics by 425.4% in the third quarter. JPMorgan Chase & Co. now owns 1,124,602 shares of the company’s stock valued at $2,361,000 after purchasing an additional 910,550 shares during the last quarter. Bain Capital Public Equity Management LLC purchased a new position in Proteostasis Therapeutics in the second quarter valued at approximately $1,233,000. Finally, Sabby Management LLC lifted its position in shares of Proteostasis Therapeutics by 109.6% during the second quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after acquiring an additional 65,451 shares in the last quarter. Institutional investors and hedge funds own 68.08% of the company’s stock.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.